Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism
Lisa M Caronia, Andrew A Dwyer, Douglas Hayden, Francesca Amati, Nelly Pitteloud, Frances J Hayes, Lisa M Caronia, Andrew A Dwyer, Douglas Hayden, Francesca Amati, Nelly Pitteloud, Frances J Hayes
Abstract
Objective: This study examines the physiological impact of a glucose load on serum testosterone (T) levels in men with varying glucose tolerance (GT).
Design: Cross-sectional study.
Patients and methods: 74 men (19-74 years, mean 51·4 ± 1·4 years) underwent a standard 75-g oral glucose tolerance test with blood sampling at 0, 30, 60, 90 and 120 min. Fasting serum glucose, insulin, total T (and calculated free T), LH, SHBG, leptin and cortisol were measured.
Results: 57% of the men had normal GT, 30% had impaired GT and 13% had newly diagnosed type 2 diabetes. Glucose ingestion was associated with a 25% decrease in mean T levels (delta = -4·2 ± 0·3 nm, P < 0·0001). T levels remained suppressed at 120 min compared with baseline (13·7 ± 0·6 vs 16·5 ± 0·7 nm, P < 0·0001) and did not differ across GT or BMI. Of the 66 men with normal T levels at baseline, 10 (15%) had levels that decreased to the hypogonadal range (<9·7 nm) at one or more time points. SHBG, LH and cortisol levels were unchanged. Leptin levels decreased from baseline at all time points (P < 0·0001).
Conclusions: Glucose ingestion induces a significant reduction in total and free T levels in men, which is similar across the spectrum of glucose tolerance. This decrease in T appears to be because of a direct testicular defect, but the absence of compensatory changes in LH suggests an additional central component. Men found to have low nonfasting T levels should be re-evaluated in the fasting state.
Trial registration: ClinicalTrials.gov NCT00433173.
© 2012 Blackwell Publishing Ltd.
Source: PubMed
Upcoming Clinical Trials
-
NCT07826949Not yet recruitingGlioma | Brain Neoplasm | Recurrent High-Grade Gliomas
-
NCT07826962Not yet recruiting
-
NCT07826975Not yet recruiting
-
NCT07826988Not yet recruitingSickle Cell Disease | Vaso-occlusive Crisis
-
NCT07827001RecruitingBrain Cancer | CNS Cancer | Nervous System Cancer | Brain Cancer Metastatic
-
NCT07827027Not yet recruiting
-
NCT07827040RecruitingAdults | Low Vision Digital Assistance | Visual Impairments
-
NCT07827053Not yet recruitingPancreatic Ductal Adenocarcinoma (PDAC)
-
NCT07827066Not yet recruitingSmoking Cessation | AI Agent | Early-Stage Cancer
-
NCT07827131Not yet recruiting